These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 21061842

  • 1. Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience.
    Cojbasić I, Macukanović-Golubović L.
    Vojnosanit Pregl; 2010 Oct; 67(10):802-6. PubMed ID: 21061842
    [Abstract] [Full Text] [Related]

  • 2. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
    Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers CL, Paquette RL, O'Dwyer ME.
    Blood; 2002 Jul 15; 100(2):435-41. PubMed ID: 12091333
    [Abstract] [Full Text] [Related]

  • 3. Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
    Cojbasić I, Macukanović-Golubović L.
    Srp Arh Celok Lek; 2010 Jul 15; 138(5-6):305-8. PubMed ID: 20607973
    [Abstract] [Full Text] [Related]

  • 4. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
    Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M.
    Blood; 2002 May 15; 99(10):3547-53. PubMed ID: 11986206
    [Abstract] [Full Text] [Related]

  • 5. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH, Johnson JR, Pazdur R.
    Clin Cancer Res; 2005 Jan 01; 11(1):12-9. PubMed ID: 15671523
    [Abstract] [Full Text] [Related]

  • 6. [Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib].
    Cojbasić I, Macukanović-Golubović L.
    Vojnosanit Pregl; 2011 Nov 01; 68(11):911-6. PubMed ID: 22191306
    [Abstract] [Full Text] [Related]

  • 7. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.
    Med Oncol; 2004 Nov 01; 21(4):349-58. PubMed ID: 15579919
    [Abstract] [Full Text] [Related]

  • 8. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL.
    Blood; 2005 May 15; 105(10):3995-4003. PubMed ID: 15657179
    [Abstract] [Full Text] [Related]

  • 9. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
    Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E, International STI571 CML Study Group.
    N Engl J Med; 2002 Feb 28; 346(9):645-52. PubMed ID: 11870241
    [Abstract] [Full Text] [Related]

  • 10. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
    Jiang Q, Chen SS, Jiang B, Jiang H, Lu Y, Lu DP.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec 18; 37(6):612-5. PubMed ID: 16378113
    [Abstract] [Full Text] [Related]

  • 11. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
    Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M.
    Clin Cancer Res; 2002 Jul 18; 8(7):2167-76. PubMed ID: 12114417
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
    Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M.
    Blood; 2007 May 15; 109(10):4143-50. PubMed ID: 17264298
    [Abstract] [Full Text] [Related]

  • 14. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP, Croom KF, Goa KL.
    BioDrugs; 2004 May 15; 18(3):207-10. PubMed ID: 15161340
    [Abstract] [Full Text] [Related]

  • 15. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
    Xu Y, Wahner AE, Nguyen PL.
    Arch Pathol Lab Med; 2004 Sep 15; 128(9):980-5. PubMed ID: 15338554
    [Abstract] [Full Text] [Related]

  • 16. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
    Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ.
    Blood; 2002 May 15; 99(10):3530-9. PubMed ID: 11986204
    [Abstract] [Full Text] [Related]

  • 17. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M.
    Clin Ther; 2007 Nov 15; 29(11):2289-308. PubMed ID: 18158072
    [Abstract] [Full Text] [Related]

  • 18. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE.
    Clin Cancer Res; 2002 Jul 15; 8(7):2177-87. PubMed ID: 12114418
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.